The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer
ConclusionsBevacizumab 10 mg/kg Q2W appears efficacious for patients with recurrent ovarian cancer, with a manageable toxicity profile. Approval of this regimen is clinically desirable for Japanese patients with ovarian cancer.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Hypertension | Japan Health | Ovarian Cancer | Ovaries | Proteinuria | Toxicology